Physician

Canopy Growth's Smiths Falls facility becomes Canada's only EU gmp-certified site combining softgel manufacturing with primary packaging of softgels, oral liquids and dried cannabis flower. MWN-AI** Summary. Canopy Growth Corporation has achieved a significant milestone with its Smiths Falls facility becoming Canada's only EU GMP-certified site for both softgel manufacturing and primary packaging. This certification was granted by the Tübingen Regional Council, the relevant medicines regulatory authority in Germany, solidifying Canopy Growth's presence in the European market. The designation allows the facility to produce and package softgels, oral liquids, and dried cannabis flower, enhancing the company's end-to-end EU GMP supply chain capabilities. As the demand for medical cannabis continues to grow across Europe, Canopy Growth's certification positions it to supply patient-ready products that meet stringent regulatory requirements. CEO Luc Mongeau emphasized the importance of this certification in accelerating their strategy for capturing value throughout their supply chain and expanding the company's footprint in European markets. The achievement at Smiths Falls builds upon Canopy Growth's commitment to quality and excellence, following a renewal of EU GMP certification at its Kincardine, Ontario facility and the expansion of its medical cannabis offerings into the UK. With a dedicated German country manager now in place, Canopy is poised for rapid commercial execution in key markets such as Germany, Poland, and the UK. The company aims to strengthen relationships with pharmacies, clinics, and healthcare professionals while expanding product choices for patients. Canopy Growth is committed to enhancing lives through cannabis, focusing on innovation and quality cultivation. It features a diverse portfolio of brands, providing medical cannabis services across Canada while also holding a non-controlling interest in Canopy USA for exposure to the U.S. THC market. The Griffiths-led strategy aims at a future where cannabis is trusted to improve well-being. MWN-AI** Analysis. Canopy Growth Corporation's recent achievement of EU GMP certification for its Smiths Falls facility positions it as a key player in the burgeoning European cannabis market. With this certification, Canopy Growth becomes the sole Canadian cannabis company with the capability to manufacture and package softgels, oral liquids, and dried cannabis flower under stringent EU regulations. This milestone enhances the company's integrated EU GMP supply chain, facilitating the delivery of patient-ready cannabis products across Europe while adhering to high quality and safety standards. Investors should view this development through a strategic lens. The EU cannabis market is evolving rapidly, driven by increasing patient demand and regulatory reforms. Canopy's certification not only showcases its operational excellence but also mitigates risk by establishing a self-contained production capability, allowing for greater control over supply and quality. Moreover, the recent appointment of a German country manager and expansion plans into key markets such as Germany, Poland, and the UK highlight the company's proactive approach to capturing market share. From a financial perspective, this strategic expansion may lead to revenue growth, bolstered by deepening relationships with healthcare providers and pharmacies. Investors should monitor Canopy's commercial execution and market penetration, as effective execution will be crucial in realizing the potential value of this certification. Stock performance can also be influenced by macroeconomic factors and competitive dynamics within the cannabis sector; thus, staying informed on regulatory developments and market trends is essential. Given these considerations, Canopy Growth appears well-positioned for growth, making it a compelling option for investors seeking exposure in the cannabis industry. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. October 13, 2026 07:30:00 am Certification strengthens Canopy Growth's European growth strategy and expands its integrated EU GMP supply chain Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that its Smiths Falls, Ontario facility ("Smiths Falls") has received European Union Good Manufacturing Practice ("EU GMP") certification for manufacturing and packaging activities from the Tübingen Regional Council (Regierungspräsidium Tübingen), Baden-Württemberg's competent medicines regulatory authority in Germany. Smiths Falls is now the only Canadian cannabis facility with EU GMP certification covering the combined scope of softgel manufacturing and primary packaging of softgels, liquids for internal use and dried cannabis flower. [1] The certification strengthens Canopy Growth's existing end-to-end EU GMP supply chain, connecting Canadian cultivation, manufacturing and packaging with its European distribution network. It expands the Company's certified capabilities for softgel manufacturing and the primary packaging of softgels, liquids for internal use and dried cannabis flower, supporting the supply of patient-ready medical cannabis products to European markets, subject to applicable product and market requirements. As regulations evolve and patient demand matures across Europe, Canopy Growth's independent and self-contained production capabilities enable it to supply an expanded medical cannabis offering entirely through its own manufacturing and packaging operations. "We have been deliberate about putting the capabilities in place to win in Europe, from high-quality cultivation and a broader portfolio to experienced commercial leadership," said Luc Mongeau, Chief Executive Officer, Canopy Growth. "This EU GMP certification adds a capability that sets us apart and accelerates our strategy to capture more value across our supply chain. It is a critical step in expanding our presence across European medical cannabis markets, strengthening our ability to serve patients, and driving profitable growth." The Smiths Falls certification builds on the Company's renewed EU GMP certification at the Kincardine, Ontario facility, the announced expansion of Canadian-grown Spectrum Therapeutics flower into the UK, and the appointment of a German country manager. With this foundation in place, Canopy Growth is focused on accelerating commercial execution across Germany, Poland and the UK, deepening relationships with pharmacies, clinics and healthcare professionals, and expanding product choices for patients. About Canopy Growth Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike. The Company's portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category-defining Storz & Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada's leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives. [1] Based on a review of certificate records in the European Medicines Agency's EudraGMDP database as of October 9, 2026. FAQ**. How does Canopy Growth Corporation WEED:CC plan to leverage its EU GMP certification to enhance its competitive advantage in the European medical cannabis market? Canopy Growth Corporation plans to leverage its EU GMP certification to establish trust with European regulators and patients, ensuring product quality and safety, while positioning itself as a leader in the European medical cannabis market. What specific strategies is Canopy Growth Corporation WEED:CC employing to deepen relationships with pharmacies and healthcare professionals in Europe? Canopy Growth Corporation is expanding its partnerships with pharmacies and healthcare professionals in Europe by focusing on educational initiatives, clinical research collaborations, and tailored product offerings to enhance accessibility and understanding of cannabis-based therapies. Given the evolving regulations in Europe, how does Canopy Growth Corporation WEED:CC assess potential risks and opportunities in expanding its product offerings? Canopy Growth Corporation assesses potential risks and opportunities in expanding its product offerings in Europe by closely monitoring regulatory changes, engaging with local authorities, and adapting its strategy to align with evolving market conditions and consumer preferences. Canopy Growth Corporation WEED:CC has appointed a German country manager; what are the key objectives for this position in relation to the expansion strategy in Europe? The key objectives for the German country manager at Canopy Growth Corporation include driving market entry, establishing strategic partnerships, navigating regulatory frameworks, and enhancing brand presence to support the company's expansion strategy in Europe. **MWN-AI FAQ is based on asking OpenAI questions about Canopy Growth Corporation (TSXC: WEED:CC).

Canopy Growth appoints Sebastian Blöte as Country Manager for Germany. Published: September 28, 2026 at 9:32a.m. EDT SMITHS FALLS, Ontario-(BUSINESS WIRE)- Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the appointment of Sebastian Blöte as Country Manager for Germany, effective October 1, 2026. Mr. Blöte will lead Canopy Growth's commercial strategy in Germany, with responsibility for expanding sales and strengthening execution across the market, deepening connections with partners and healthcare professionals, and driving growth to fully capture the significant potential of the German medical cannabis market. The appointment of Mr. Blöte builds on the progress Canopy Growth has made over the past year to strengthen its international medical cannabis business, including enhancing its European Union Good Manufacturing Practice supply capabilities from its Canadian cultivation operations. "Over the last year, we have put the pieces in place to build a stronger international medical cannabis business, delivering double-digit sequential growth for the past three quarters," said Luc Mongeau, Chief Executive Officer, Canopy Growth. "We have strengthened our cultivation and supply capabilities, broadened our portfolio and sharpened our commercial focus. Bringing Sebastian into the business is the next step in that strategy, adding more experienced leadership on the ground as we look to accelerate growth and capture more of the opportunity we see in Germany and across Europe." Mr. Blöte brings more than a decade of commercial leadership in the European cannabis industry. He most recently served as European Sales Director, then Digital Sales Director, at a leading European medical cannabis company based in Germany, leading its Swiss market entry, and a product launch in Austria. Earlier in his career, Mr. Blöte co-founded and led a medical cannabis import and distribution company in Germany. "I'm excited to build deeper relationships with clinics, pharmacies and healthcare professionals to better understand what they need from us and translate that into stronger commercial execution," said Sebastian Blöte. "Germany has a large and evolving medical cannabis ecosystem and Canopy Growth has the portfolio, supply capabilities and infrastructure in place; the opportunity now is to build on that foundation and increase the pace at which we grow." About Canopy Growth Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike. The Company's portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category-defining Storz & Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada's leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives. View source version on businesswire.com: https://www.businesswire.com/news/home/20260928356246/en/ Media Contact:[email protected] Investor Contact:[email protected] Business Wire

Canopy Growth Corporation has appointed Sebastian Blöte as country manager for Germany, effective 1 October 2026. Blöte will lead the company's commercial strategy in Germany, focusing on expanding sales and strengthening partnerships with healthcare professionals in the medical cannabis market. Blöte brings over a decade of commercial leadership experience in the European cannabis industry. He previously served as European sales director and digital sales director at a leading European medical cannabis company, where he led market entries in Switzerland and Austria. Earlier, he co-founded a medical cannabis import and distribution company in Germany. The appointment follows Canopy Growth's recent efforts to strengthen its international medical cannabis business, which has delivered double-digit sequential growth for three consecutive quarters.